4960 Peachtree Industrial Blvd.
Norcross, GA, 30071 United States
Galectin Therapeutics has a knack for inhibiting galectin proteins. The drug developer is targeting galectin proteins as they play a key role in the development of a variety of diseases. It is developing such inhibitors to treat liver fibrosis, which is currently untreatable. Its GM-CT-01 drug candidate is being investigated for use targeting certain melanomas and in combination with another drug to improve its effectiveness in treating colorectal cancer. Galectin Therapeutics is focused on diseases with serious, life-threatening consequences and on diseases for which there is little to no current treatment available.